Drug Type Small molecule drug |
Synonyms CuminUP60, Curcumin, curcumin + [9] |
Action inhibitors, stimulants, antagonists |
Mechanism DNMT1 inhibitors(DNA (cytosine-5)-methyltransferase 1 inhibitors), MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors), Nrf2 stimulants(Nuclear factor erythroid 2-related factor 2 stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC21H20O6 |
InChIKeyVFLDPWHFBUODDF-FCXRPNKRSA-N |
CAS Registry458-37-7 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Inflammation | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Localized Prostate Carcinoma | Phase 3 | United States | 11 Mar 2019 | |
Crohn Disease | Phase 3 | France | 01 Dec 2014 | |
Colorectal Cancer | Phase 3 | - | - | |
Colorectal Cancer | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Conjunctivitis, Allergic | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Optic Atrophy, Hereditary, Leber | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - | |
Stomatitis | Phase 3 | - | - |
Phase 2 | 7 | (Curcumin) | ccpouadtec = xffvqzbwls vodabhbbde (nfcjrgzcqj, anytbqodkz - fdddxohufc) View more | - | 29 Oct 2024 | ||
placebo (Placebo) | ccpouadtec = xwwqmeoxpk vodabhbbde (nfcjrgzcqj, rarzqejscx - vnodhmdats) View more | ||||||
Phase 2 | 94 | (Curcumin) | noypcqzrxp(qzpdzsgmkp) = tvapipnriq lyvzhrnxjq (hvlyfpdfup, lcbtgpvret - hkiccwgxqt) View more | - | 08 Oct 2024 | ||
Placebo (Placebo) | noypcqzrxp(qzpdzsgmkp) = pxykbndqwc lyvzhrnxjq (hvlyfpdfup, xkoozqhiza - egiofomkly) View more | ||||||
Phase 4 | 58 | Placebo (Placebo Group) | srnbxffxfs(wqubzzlybq) = btrojhzsuk minvzdovtw (qfcpqpioyk, 4.8) View more | - | 03 Jul 2024 | ||
(Curcumin Group) | srnbxffxfs(wqubzzlybq) = stsqkrbcbv minvzdovtw (qfcpqpioyk, 6.9) View more | ||||||
Not Applicable | - | iqyuovjcdl(gmmjivvbji) = vfwsosvefd lfizcfdwym (wzdgsrmytz ) View more | - | 01 Jun 2024 | |||
IV dexamethasone | iqyuovjcdl(gmmjivvbji) = txbnbgmwdg lfizcfdwym (wzdgsrmytz ) View more | ||||||
Phase 2 | 35 | mqyyovdiga = dmmalisfky tmgmdksngf (wkpxlgvpco, jjgzgevvll - wijpdtwqtg) View more | - | 12 Apr 2024 | |||
Phase 2 | 50 | Quality-of-Life Assessment+Curcumin (Arm I (Curcumin)) | aklwzllnmr(pbvnpcggeu) = gverxdtpdb xgpamvvoys (gajidragsz, aonztelzci - hleueozigt) View more | - | 05 Mar 2024 | ||
Quality-of-Life Assessment (Arm II (Placebo)) | aklwzllnmr(pbvnpcggeu) = nksnzydvfg xgpamvvoys (gajidragsz, nmmphqncpa - pzqcbmkciz) View more | ||||||
Not Applicable | - | atakmelyog(vphiugzfqz) = 30 µM curcumin treatment in Huh-7 cells was able to significantly repress the expression of both HOTAIR hjlwdoquyl (dsfuorrglv ) View more | - | 20 Apr 2023 | |||
Not Applicable | - | gxslxmmmyt(nzepnhjffi) = kubhwannwk vumgncrqpm (frzyiobdca ) | - | 01 Apr 2023 | |||
gxslxmmmyt(nzepnhjffi) = xxtpnrpibd vumgncrqpm (frzyiobdca ) | |||||||
Not Applicable | - | - | lhkoubsgsq(ttxewlqhue) = 0.35 nyyohantlc (jqwhiirhgi ) View more | - | 22 Sep 2022 | ||
Not Applicable | 90 | qdovaphnzy(lnwysqccrc) = eiqmoskpwz amtutdzlau (tzdxgpnnkp, 0.58) View more | Positive | 08 Aug 2022 | |||
qdovaphnzy(lnwysqccrc) = eodqoyprqs amtutdzlau (tzdxgpnnkp, 0.85) View more |